Verastem, Inc. (VSTM) vs Zevra Therapeutics, Inc. (ZVRA)

Verastem, Inc. and Zevra Therapeutics, Inc. are both Biotechnology companies. Verastem, Inc. and Zevra Therapeutics, Inc. are of similar size ($694.6M and $668.7M). Verastem, Inc. has negative trailing earnings, so its P/E is not meaningful; Zevra Therapeutics, Inc. trades at 11.6×. Verastem, Inc. grew revenue faster over the last twelve months: 472.9% against 119.4%. Zevra Therapeutics, Inc. has the higher net margin (42.3% vs −231.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Zevra Therapeutics, Inc. leads on 15 and Verastem, Inc. on 2.

Valuation

Metric VSTM ZVRA Biotechnology median
P/E n/m 11.62 7.88
P/S 8.89 4.80 11.47
P/B 15.56 3.00 2.52
Price to free cash flow n/m 19.75 21.16
EV/EBITDA n/m 6.59 0.74
EV/Sales 8.29 3.90 10.73
Earnings yield (31.66%) 8.61% (28.84%)
Free cash flow yield (20.85%) 5.06% (23.03%)

Profitability

Metric VSTM ZVRA Biotechnology median
Gross margin 86.35% 95.46% 65.16%
Operating margin (182.57%) 60.54% 0.00%
Net margin (231.59%) 42.25% 0.00%
Free cash flow margin (185.31%) 24.30% 0.00%
Return on equity (471.16%) 34.33% (57.72%)
Return on assets (100.65%) 20.57% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric VSTM ZVRA Biotechnology median
Revenue growth (TTM) 472.89% 119.40% 5.64%
EPS growth (last fiscal year) 17.49% 159.21% —
Revenue growth, 5-year CAGR 12.11% 51.62% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric VSTM ZVRA Biotechnology median
Debt to equity 1.48 0.00 0.00
Current ratio 2.25 5.17 4.73
Net debt to EBITDA 0.76 39.03 0.96

Dividend

Metric VSTM ZVRA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric VSTM ZVRA Biotechnology median
Market cap 694.62m 668.66m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack